Engineered nucleic acid-targeting nucleic acids
Inventors
Donohoue, Paul Daniel • May, Andrew Paul
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
Core Innovation
The invention provides a cell containing Class 2 Type II CRISPR-Cas9-associated discontinuous first-stem polynucleotides comprising separate dfs1-PN and target-binding dfs2-PN components. Complementary sequences base-pair to form upper stem and bulge elements, while fragment sequences pair with a lower stem sequence to form a lower stem element. The components assemble with a nexus sequence and 3′ hairpin element into a Cas9 nucleoprotein complex for target nucleic acid binding and cleavage.
The claim defines two alternative arrangements for the discontinuous polynucleotide components positioning the upper stem, bulge, and lower stem sequences across dfs1-PN and dfs2-PN. Documented applications encompass genome modification, transcriptional modulation, cellular editing analysis, and an AAVS-1 in-vitro cleavage assay. Because the background section is omitted in the provided content, the problem being solved is not explicitly described in patent.
Claims Coverage
The supplied relevant claims identify one independent claim with two inventive features, covering a cell comprising paired dfs1-PN and dfs2-PN components in either of two alternative arrangements.
First arrangement of the discontinuous polynucleotides
The cell comprises a dfs1-PN containing fragment nucleotide sequence 1, bulge element nucleotide sequence II, upper stem element nucleotide sequence II, linker sequences, upper stem element nucleotide sequence I, bulge element nucleotide sequence I, lower stem element nucleotide sequence I, a nexus nucleotide sequence, and a 3′ hairpin element, and a dfs2-PN containing a nucleic acid target binding sequence and fragment nucleotide sequence 2. The upper stem sequences base-pair to form an upper stem element, the bulge sequences form a bulge element, and the fragment nucleotide sequences pair with lower stem element nucleotide sequence I to form a lower stem element.
Second arrangement of the discontinuous polynucleotides
The cell comprises a dfs1-PN containing fragment nucleotide sequence 1, linker sequences, a nexus nucleotide sequence, and a 3′ hairpin element, and a dfs2-PN containing a nucleic acid target binding sequence, lower stem element nucleotide sequence II, bulge element nucleotide sequence II, upper stem element nucleotide sequence II, upper stem element nucleotide sequence I, bulge element nucleotide sequence I, and fragment nucleotide sequence 2. The upper stem sequences base-pair to form an upper stem element, the bulge sequences form a bulge element, and the fragment nucleotide sequences pair with lower stem element nucleotide sequence II to form a lower stem element.
The independent claim covers two alternative arrangements of dfs1-PN and dfs2-PN in a cell, each forming upper stem, bulge, and lower stem elements.
Stated Advantages
Altered target and Cas9 binding.
Activatable or nuclease-resistant configurations.
Screening flexibility.
Support for delivery using smaller dfs2-PN components.
Documented Applications
Genome modification.
Transcriptional modulation.
Cellular editing analysis, including examples involving HEK293 cells.
AAVS-1 in-vitro cleavage assay.
Interested in licensing this patent?